Symplmed Pharmaceuticals LLC
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Symplmed Pharmaceuticals LLC
FDA Starts 2015 As It Plans To Go On: A Spate Of Approvals, A Full Slate Of Possibilities
With more than 40 novel agents under FDA review – and seven approvals already – prospects are good for 2015 to be another stellar year for new molecular entity and novel biologic approvals. Supplemental indications with “breakthrough” designations and the first biosimilars could challenge the primacy of NMEs in the approval narrative.
FDA Starts 2015 As It Plans To Go On: A Spate Of Approvals, A Full Slate Of Possibilities
With more than 40 novel agents under FDA review – and six approvals already – prospects are good for 2015 to be another stellar year for new molecular entity and novel biologic approvals. Supplemental indications with “breakthrough” designations and the first biosimilars could challenge the primacy of NMEs in the approval narrative.
FDA Approvals, In Brief: Novartis’ Meningitis Vaccine Bexsero Gets Early Nod
Also, Rockwell’s iron deficiency treatment Triferic gains agency approval, but without a dose-sparing claim related to erythropoiesis-stimulating agents; Symplmed’s perindopril/amlodipine fixed-dose combination approved for hypertension.
Deals Shaping The Medical Industry, September 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced June-August 2014.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Symplmed Pharma
- SYMPLMED TECHNOLOGIES, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice